FDA OKs Varubi IV

November 1, 2017

The FDA approved an intravenous formulation of Tesaro’s anti-nausea drug Varubi (rolapitant) for chemotherapy patients, the company said.

The agency approved an oral formulation of Varubi in 2015.

The IV drug was approved for use in combination with other antiemetics to treat adults experiencing delayed nausea and vomiting after chemotherapy.

View today's stories